

VIVANZA BIOSCIENCES LIMITED

(Formerly known as Ijee Injectaa Limited)

Regd. Office: 702, 'A' Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

Phone: 079 – 65410862 email: info@vivanzabiosciences.com CIN: L24110GJ1982PLC005057

May 30, 2018

To,
Department of Corporate Services
BSE Limited
25th Floor, P. J. Tower,
Dalal Street,
Fort, Mumbai- 400 001

Dear Sir/Madam,

Sub: Outcome of Board Meeting

This is to inform you that the Board of Directors of the Company in its meeting held today i.e. on Wednesday, May 30, 2018 from 4:00 p.m. to 5:00 p.m., at the Registered Office of the Company, inter alia have;

1. considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2018 along with Audit Report thereon as per Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. took note of resignations of Ms. Sheetal Pandya and Mr. Harshul K. Shah from the post of Independent Directors of the Company.
3. shifted the registered office of the Company from 702, 'A' Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006 to 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

The agenda for appointment of Woman Director on the Board as per Regulation 17(1) (a) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 has not been considered by the Board and hence postponed.

Please take the above on your records.

Yours faithfully,



VIVANZA BIOSCIENCES LIMITED

(Formerly known as Ivec Injectaa Limited)

Regd. Office: 702, 'A' Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

Phone: 079 – 65410862 email: info@vivanzabiosciences.com CIN: L24110GJ1982PLC005057

For Vivanza Biosciences Limited



Naveen Jain

Director

DIN: 05154306

Encl:

1. Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2018.
2. Audit Report on Standalone and Consolidated Financial Results.
3. Declaration on Audit Report with Unmodified opinion.

VIVANZA BIOSCIENCES LIMITED

(Formerly known as Ijee Injectaa Limited)

Regd. Office: 702, 'A' Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

Phone: 079 – 65410862 email: info@vivanzabiosciences.com CIN: L24110GJ1982PLC005057

May 30, 2018

To,
Department of Corporate Services
BSE Limited
25th Floor, P. J. Tower,
Dalal Street,
Fort, Mumbai- 400 001.

Dear Sir/Madam,

DECLARATION

I, Naveen Jain, Director of Vivanza Biosciences Limited having its registered office at 702, "A" Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad – 380 006, hereby declare that, the Statutory Auditors of the Company, M/s. GMCA & Co., Chartered Accountants (FRN: 109850W) have issued an Audit Report with unmodified opinion on Audited Standalone & Consolidated Financial Results for the quarter and year ended on 31st March, 2018.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated 25th May, 2016.

For Vivanza Biosciences Limited



Naveen Jain

Director

DIN: 05154306



Auditor's Report on Annual Consolidated Ind AS Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors Of
M/s Vivanza Biosciences Limited

1. We have audited the accompanying Statement of Consolidated Financial Results of **Vivanza Biosciences Limited** ("the company") and its subsidiaries (the company and its subsidiaries together referred to as "the group") for the quarter and year ended March 31, 2018 ("the statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, as modified Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
 2. This Statement is responsibility of the Company's Management and is approved by the Board of Directors. The Statement, as it relates to the quarter ended March 31, 2018, has been compiled from the related interim consolidated financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) and as it relates to the year ended March 31, 2018, has been compiled from the related annual consolidated financial statements prepared in accordance with Indian Accounting Standard, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such interim consolidated financial statement and annual consolidated financial statement
 3. We conducted our audit in accordance with the Standard on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amount disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
- The statement includes the financial result of M/s Vivanza Lifesciences Private Limited.

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad - 380009
☎ 079-40037372 ✉ gmca1973@gmail.com






GMCA & Co.

Chartered Accountants

4. We did not audit the financial statements of above subsidiary. These financial statement have been audited by other auditor whose report has been furnished to us by the management and our opinion on consolidated financial statement, in so far as it relates to amount discloses included in respect of these subsidiaries, jointly controls entities in preparation of this report.
5. In our opinion and to the best of our information and according to the explanations given to us, consolidate financial results:
 - i. Include the result of Subsidiary Company M/s Vivanza Lifesciences Private Limited.
 - ii. Gives a true and fair view of the net profit and other Financial Information in conformity with the aforesaid Indian Accounting standard (Ind AS) and Other Accounting Principles generally accepted in India of consolidated profit and total comprehensive income for the period & other financial information of group for the quarter & year ended march,31 2018.
6. Further we report the figures for the quarter ended March, 31 2018 as reported in these financial result, which are the balancing figures between the audited figures in respect of full financial year and published year to date figure up to the end of the third quarter of the financial year. Also the figure up to end of third quarter had only been reviewed and not subjected to audit.
7. The Comparative Financial Information for the year end March 31, 2017 prepared in accordance with Ind AS included in statement have been audited by us. The Report of the previous year on these Comparative Financial Information dated May 30, 2017 expressed an Unmodified Opinion.



For, G M C A & Co.
Chartered Accountants
FRN: 109850W


CA. Mitt S. Patel
Partner

Membership No. 163940

Date: 30th May, 2018

Place: Ahmedabad

VIVANZA BIOSCIENCES LIMITED
(Formerly Known as IVEE INJECTAA LTD)

Registered Office, 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.
CIN : L24110GJ1982PLC005057

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND YEAR MARCH 31, 2018.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	122.25	199.79	252.60	644.03	347.46
(b) Other Income	0.00	0.00	4.34	0.11	4.53
Total Income	122.25	199.79	256.94	644.14	351.99
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	311.34	179.19	365.08	600.24	487.77
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-209.12	0.26	-138.98	-47.31	-181.00
(d) Employee benefits expense	0.61	1.52	0.91	13.73	41.63
(e) Finance Cost	7.73	10.41	4.24	35.62	4.28
(f) Depreciation and amortisation expense	0.00	0.00	-0.04	0.00	0.00
(g) Other expenses	4.51	0.58	12.93	18.51	30.46
Total Expenses	115.06	191.96	244.13	620.78	383.14
3 Profit/(loss) before exceptional items and tax (1-2)	7.19	7.83	12.81	23.35	-31.14
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	7.19	7.83	12.81	23.35	-31.14
6 Tax Expense					
(a) Current tax	2.81	0.00	0.00	2.81	0.00
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00
Total Tax Expenses	2.81	0.00	0.00	2.81	0.00
7 Profit / (Loss) for the period from continuing operations (5-6)	4.38	7.83	12.81	20.54	-31.14
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after tax)(8-9)	0.00	0.00	0.00	0.00	0.00
11 Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00	0.00
12 Minority Interest *	0.00	0.00	0.00	0.00	0.00
13 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
14 Total Comprehensive Income for the period	4.38	7.83	12.81	20.54	-31.14
15 Total Comprehensive Income attributable to :					
Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00	0.00
Minority Interest *	0.00	0.00	0.00	0.00	0.00
16 Paid-up equity share capital (Face value of Rs.10/- each)	400	400	400	400	400
17 Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	0.11	0.20	0.32	0.51	-0.78
(b) Diluted	0.11	0.20	0.32	0.51	-0.78
18 Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	0.11	0.20	0.32	0.51	-0.78
(b) Diluted	0.11	0.20	0.32	0.51	-0.78

Notes:

1. The above audited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 30, 2018. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2018.

2. The Company adopted the Indian Accounting Standards (Ind AS) effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Ind AS compliant figures for the corresponding quarter ended 31st March 2017, and year ended 31 March 2017, including the reconciliation of profit/(loss) under Ind AS of the corresponding quarter/year with the profit reported under previous GAAP, have not been subjected to limited review or audit. However the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the affairs of the Company.

4. Reconciliation of Net Profit/(Loss) as reported earlier (referred to as Indian GAAP) vis-à-vis Ind AS is given below:

Particulars	Quarter ended 31.03.2017	Year ended 31.03.2017
Net Profit/(Loss) as per previous Indian GAAP	12.81	-31.14
Adjustments	0.00	0.00
Net Profit/(Loss) before other comprehensive income as per Ind AS	12.81	-31.14
Add: Other Comprehensive Income (net of tax)	0.00	0.00
Total comprehensive income as per Ind AS	12.81	-31.14

5. Reconciliation of Total Equity as on 31.03.2017 as per previous GAAP and Ind AS

Particulars	Year ended 31.03.2017
Total Equity as per Previous Indian GAAP	352.54
Less : Impact of Derecognition of Preliminary Expense	0.00
Add : Impact of Investment Measured at Fair Value Through Profit & Loss	0.00
Add : Deferred Tax on Above	0.00
Total Equity as per Ind AS	352.54

6. The Company operates only in single segment i.e. pharmaceuticals related activities

Date : 30/05/2018
Place : Ahmedabad

For VIVANZA BIOSCIENCES LIMITED


DIRECTOR

VIVANZA BIOSCIENCES LIMITED		
STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES		
(Rs.in Lacs)		
Particulars	As at 31/03/2018	As at 31/03/2017
A	ASSETS	
1	Non-current Assets	
(a)	Property , Plant and Equipment	67.82
(b)	Other Intangible assets	3.00
(c)	Goodwill	160.54
(d)	Capital work in progress	-
(e)	Intangible assets under development	-
(f)	Financial Assets :	
(i)	Investments	0.25
(ii)	Deferred tax assets (Net)	-
(iii)	Loans	75.36
(iv)	Other non-current assets	-
	Sub-total - Non-current Assets	306.97
2	Current Assets	
(a)	Inventories	228.31
(b)	Financial Assets :	
(i)	Investments	-
(ii)	Trade Receivables	507.39
(iii)	Cash and Cash Equivalents	7.72
(iv)	Loans	251.28
(c)	Other current assets	18.42
	Sub-total - Current Assets	1,013.13
	TOTAL - ASSETS	1,320.11
B	EQUITY AND LIABILITIES	
	Shareholders' Funds	
(a)	Share Capital	400.00
(b)	Other Equity	(47.46)
	Sub-total - Shareholders' Funds	373.08
1	Liabilities	
	Non-current Liabilities	
(a)	Financial Liabilities :	
(i)	Borrowings	55.67
(b)	Deferred Tax Liabilities (Net)	-
(c)	Provisions	-
(d)	Other Non - Current Liabilities	-
	Sub-total - Non-current liabilities	55.67
2	Current Liabilities	
(a)	Financial Liabilities :	
(i)	Borrowings	380.94
(ii)	Trade Payables	483.58
(b)	Other Financial Liabilities	-
(c)	Provisions	4.95
(d)	Other Current Liabilities	21.88
	Sub-total - Current Liabilities	891.36
	TOTAL - EQUITY AND LIABILITIES	1,320.11





**Auditor's Report on Annual Standalone Ind AS Financial Results of the Company
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

To,
The Board of Directors
Vivanza Biosciences Limited

1. We have audited the accompanying Statement of Annual Standalone Ind AS Financial Results of Vivanza Biosciences Limited ("the Company") for the year ended March 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and approved by the Board of Directors. This Statement has been prepared on the basis of the annual Ind AS financial statements. Our responsibility is to express an opinion on this Statement, based on our audit of such annual Ind AS financial statements, which have been prepared in accordance with the Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules thereon and other accounting principles generally accepted in India.
2. We conducted our audit of the Statement in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the Statement. An audit also includes assessing the accounting principles used and significant estimates made by management.
3. We believe that the audit evidences obtained by us are sufficient and appropriate to provide a reasonable basis for our opinion on the Statement.
4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and



Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad – 380009
☎ 079-40037372 ✉ gmca1973@gmail.com



GMCA & Co.

Chartered Accountants

(ii) gives a true and fair view of the Net Profit (including other comprehensive income) and other financial information of the Company for the year ended March 31, 2018.

5. The statement includes the results for the Quarter ended March 31, 2018, being the balancing figure between audited figures in respects of full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Place: Ahmedabad

Date: 30.05.2018

For, G M C A & Co.

Chartered Accountants

FRN: 109850W



CA. Mitt S. Patel

Partner

Membership No. 163940

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad – 380009
☎ 079-40037372 ✉ gmca1973@gmail.com

VIVANZA BIOSCIENCES LIMITED
(Formerly Known as IVEE INJECTAA LTD)

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.
CIN : L24110GJ1982PLC005057

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND YEAR ENDED MARCH 31, 2018.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	122.26	199.79	252.60	644.03	347.47
(b) Other Income	0.00	0.00	4.12	0.11	4.53
Total Income	122.26	199.79	256.72	644.14	352.00
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	311.33	179.19	365.08	600.24	487.77
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-209.12	-0.26	-138.99	-47.31	-181.00
(d) Employee benefits expense	0.18	0.53	-2.10	10.42	30.47
(e) Finance Cost	8.74	10.45	4.25	35.56	4.25
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
(g) Other expenses	3.37	1.06	8.98	18.42	26.39
Total Expenses	114.50	190.97	237.22	617.33	367.88
3 Profit/(loss) before exceptional items and tax (1-2)	7.76	8.82	19.50	26.81	-15.88
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	7.76	8.82	19.50	26.81	-15.88
6 Tax Expense					
(a) Current tax	2.81	0.00	0.00	2.81	0.00
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00
Total Tax Expenses	2.81	0.00	0.00	2.81	0.00
7 Profit / (Loss) for the period from continuing oprations (5-6)	4.95	8.82	19.50	24.00	-15.88
8 Profit (Loss) from discontinuing oprations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing oprations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing oprations (after tax)(8-9)	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (I) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(i) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	4.95	8.82	19.50	24.00	-15.88
13 Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400
14 Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	0.12	0.22	0.49	0.60	-0.40
(b) Diluted	0.12	0.22	0.49	0.60	-0.40
15 Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	0.12	0.22	0.49	0.60	-0.40
(b) Diluted	0.12	0.22	0.49	0.60	-0.40

Notes:

- The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on May 30, 2018. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2018.
- The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
- The Ind AS compliant figures for the corresponding quarter ended 31st March 2017, and year ended 31st March 2017, including the reconciliation of profit/(loss) under Ind AS of the corresponding quarter/year with the profit reported under previous GAAP, have not been subjected to limited review or audit. However the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the affairs of the Company.

4. Reconciliation of Net Profit/(Loss) as reported earlier (referred to as Indian GAAP) vis-à-vis Ind AS is given below:

Particulars	Quarter ended 31.03.2017	Year ended 31.03.2017
Net Profit/(Loss) as per previous Indian GAAP	19.50	-15.88
Adjustments	0.00	0.00
Net Profit/(Loss) before other comprehensive income as per Ind AS	19.50	-15.88
Add: Other Comprehensive Income (net of tax)	0.00	0.00
Total comprehensive income as per Ind AS	19.50	-15.88

5. Reconciliation of Total Equity as on 31.03.2017 as per previous GAAP and Ind AS

Particulars	Year ended 31.03.2017
Total Equity as per Previous Indian GAAP	367.81
Less : Impact of Derecognition of Preliminary Expense	0.00
Add : Impact of Investment Measured at Fair Value Through Profit & Loss	0.00
Add : Deferred Tax on Above	0.00
Total Equity as per Ind AS	367.81

6. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

Date : 30/05/2018
Place : Ahmedabad


DIRECTOR

VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF STANDALONE ASSETS AND LIABILITIES			
(Rs.in Lacs)			
	Particulars	As at 31/03/2018	As at 31/03/2017
A	ASSETS		
1	Non-current Assets		
(a)	Property , Plant and Equipment		-
(b)	Other Intangible assets		-
(c)	Capital work in progress		-
(d)	Intangible assets under development		-
(e)	Financial Assets :		
(i)	Investments	191.45	191.45
(ii)	Deferred tax assets (Net)	-	-
(iii)	Loans	59.33	59.33
(iv)	Other non-current assets	-	-
	Sub-total - Non-current Assets	250.78	250.78
2	Current Assets		
(a)	Inventories	228.31	181.00
(b)	Financial Assets :		
(i)	Investments		-
(ii)	Trade Receivables	507.39	252.83
(iii)	Cash and Cash Equivalents	2.28	31.51
(iv)	Loans	263.04	223.40
(c)	Other current assets	18.42	18.42
	Sub-total - Current Assets	1,019.44	707.16
	TOTAL - ASSETS	1,270.23	957.94
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	-8.20	(32.19)
	Sub-total - Shareholders' Funds	391.80	367.81
1	Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	-	-
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	-	-
2	Current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	380.94	318.06
(ii)	Trade Payables	483.58	255.69
(b)	Other Financial Liabilities		-
(c)	Provisions	4.64	4.99
(d)	Other Current Liabilities	9.26	11.40
	Sub-total - Current Liabilities	878.42	590.14
	TOTAL - EQUITY AND LIABILITIES	1,270.23	957.94

[Handwritten Signature]